| Literature DB >> 25973032 |
Xing Wang1, Juan Zhang2, Liang Zhou3, Peng Lu1, Zhi-Gang Zheng1, Wei Sun1, Jian-Lin Wang1, Xi-Sheng Yang1, Xiao-Lei Li1, Ning Xia1, Ning Zhang1, Ke-Feng Dou1.
Abstract
MicroRNAs (miRNAs) are associated with human carcinogenesis and tumor development. Moreover, serum miRNAs can reflect the level of tissue miRNAs and be potential tumor markers. Serum microRNA-21 (miR-21) is overexpressed in many human cancers including hepatocellular carcinoma (HCC). However, how serum miR-21 changes during the HCC formation and whether miR-21 plays a regulatory role in this whole process are unknown. The current study evaluated the prognostic and diagnostic potential of serum miR-21 in HCC patients. Next, we established a HCC rat model and collected the blood and liver tissues at regular time points. AFP from the serum, RNA from the serum and liver tissues were collected and quantified separately. The results revealed that tissue and serum miR-21 was upregulated significantly in the groups of cirrhosis, early and advanced HCC compared with normal and fibrosis groups. The AFP levels were increased in early and advanced HCC compared with other groups. Then, the changes of miR-21 downstream proteins (i.e., programmed cell death 4 [PDCD4] and phosphatase and tensin homolog [PTEN]) in the liver tissues were measured. PDCD4 and PTEN expression was decreased gradually after tumor induction and negatively correlated with miR-21 expression. All these results suggested that serum miR-21 was associated with the prognosis of HCC; the changes in serum miR-21 were earlier and more accurately reflected the pathogenesis of HCC than AFP; therefore, it could be used as an early diagnostic marker for HCC. Our in vivo experiments further confirmed that miR-21 plays an important role in promoting the occurrence and development of HCC by regulating PDCD4 and PTEN.Entities:
Keywords: Hepatocellular carcinoma; biomarker; diagnosis and prognosis; microRNA; microRNA-21; serum
Mesh:
Substances:
Year: 2015 PMID: 25973032 PMCID: PMC4396214
Source DB: PubMed Journal: Int J Clin Exp Pathol ISSN: 1936-2625